• Jintong He, Chong Liu, Tian Li, Yewei Liu, Shuncong Wang, Jian Zhang, Lei Chen, Chao Wang, Yuanbo Feng, Giuseppe Floris, Zhiqiang Wang, Xian Zhang, Liwen Zhao, Yue Li, Haibo Shao, and Yicheng Ni.
• Department of Interventional Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
• Int J Med Sci. 2020 Jan 1; 17 (15): 2269-2275.

AbstractCancer vasculature is immature, disorganized and hyperpermeable and can serve as a target for anti-cancer therapies. Vascular disrupting agents (VDAs) are tubulin protein binding and depolymerizing agents that induce rapid tumoral vascular shutdown and subsequent cancer necrosis. However, two clinical problems exist with all VDAs, i.e. 1) incomplete anticancer effect and 2) dose-dependent toxicity. To tackle these problems, in our ongoing research, a novel VDA C118P is applied by transarterial administration of half the intravenous dose in rabbits with implanted VX2 liver tumor to assess its therapeutic efficacy. Nearly complete tumor necrosis was achieved by only a single arterial dose of C118P at 5 mg/kg, which was documented in a representative case by in vivo digital subtraction arteriogram (DSA) and magnetic resonance imaging (MRI), and further confirmed by ex vivo microangiogram and histopathology. This convincing and promising preliminary outcome would warrant further comprehensive studies to explore the potentials of VDAs by transarterial administration either in mono-drug or in combination for management of solid cancers.© The author(s).

35 keywords...

hide…